Abstract:Background: Identifying novel regulatory factors and uncovered mechanisms of somatic cell reprogramming will be helpful for basic research and clinical application of induced pluripotent stem cells (iPSCs). Sin3a, a multifunctional transcription regulator, has been proven to be involved in the maintenance of pluripotency in embryonic stem cells (ESCs), but the role of Sin3a in somatic cell reprogramming remains unclear. Methods: RNA interference of Sin3a during somatic cell reprogramming was realized by short hairpin RNAs. Reprogramming efficiency was evaluated by the number of alkaline phosphatase (AP)-positive colonies and Oct4-GFP-positive colonies. RNA sequencing was performed to identify the influenced biological processes after Sin3a knockdown and further confirmed by quantitative RT-PCR (qRT-PCR), western blotting and flow cytometry. The interaction between Sin3a and Tet1 was detected by coimmunoprecipitation. The enrichment of Sin3a and Tet1 at the epithelial gene promoters was measured by chromatin immunoprecipitation. Furthermore, DNA methylation patterns at the gene loci were investigated by hydroxymethylated DNA immunoprecipitation. Finally, Sin3a mutants that disrupt the interaction of Sin3a and Tet1 were also introduced to assess the importance of the Sin3a-Tet1 interaction during the mesenchymal-to-epithelial transition (MET) process. Results: We found that Sin3a was gradually increased during OSKM-induced reprogramming and that knockdown of Sin3a significantly impaired MET at the early stage of reprogramming and iPSC generation. Mechanistic studies showed that Sin3a recruited Tet1 to facilitate the hydroxymethylation of epithelial gene promoters. Moreover, disrupting the interaction of Sin3a and Tet1 significantly blocked MET and iPSC generation. Conclusions: Our studies revealed that Sin3a was a novel mediator of MET during early reprogramming, where Sin3a functioned as an epigenetic coactivator, cooperating with Tet1 to activate the epithelial program and promote the initiation of somatic cell reprogramming. These findings highlight the importance of Sin3a in the MET process and deepen our understanding of the epigenetic regulatory network of early reprogramming.

AP-1 activity is a major barrier of human somatic cell reprogramming

Improving the Reprogramming Efficiency of Somatic Cells to Induced Pluripotent Stem Cells.

Epigenetic regulation of somatic cell reprogramming

H3K9 Methylation is a Barrier During Somatic Cell Reprogramming into Ipscs.

Generation of Human-Induced Pluripotent Stem Cells in the Absence of Exogenous Sox2

Shared Gene Regulation During Human Somatic Cell Reprogramming

B1 SINE-binding ZFP266 Impedes Mouse Ipsc Generation Through Suppression of Chromatin Opening Mediated by Reprogramming Factors.

Identification of New Transcription Factors that Can Promote Pluripotent Reprogramming

Chromatin Landscape Dynamics During Reprogramming Towards Human Naïve and Primed Pluripotency Reveals the Divergent Function of PRDM1 Isoforms.

Chromatin Accessibility Dynamics During Ipsc Reprogramming.

The oncogene c-Jun impedes somatic cell reprogramming

Sin3a drives mesenchymal-to-epithelial transition through cooperating with Tet1 in somatic cell reprogramming

Nurd Blocks Reprogramming of Mouse Somatic Cells into Pluripotent Stem Cells

Remodeling of Epigenetic Landscape During Induced Somatic Cell Reprogramming

Mechanisms underlying the formation of induced pluripotent stem cells

Chromosomal aberration arises during somatic reprogramming to pluripotent stem cells

B1 SINE-binding ZFP266 impedes reprogramming through suppression of chromatin opening mediated by pioneering factors

Subtelomeric Hotspots of Aberrant 5-Hydroxymethylcytosine-mediated Epigenetic Modifications During Reprogramming to Pluripotency.

Microenvironmental cues influence the reprogramming of somatic cells to induced pluripotent stem cells

Intrachromosomal looping is required for activation of endogenous pluripotency genes during reprogramming.

Linking Incomplete Reprogramming to the Improved Pluripotency of Murine Embryonal Carcinoma Cell-Derived Pluripotent Stem Cells